Chelsea (London)
Key Information
Salary: Dependent on relevant Postdoctoral experience, salary scale £38,607- £45,224. Future progression is based on annual performance review. If the candidate has not yet been awarded their PhD, the starting salary will be at £32,844 per annum until the successful completion of their viva.
This role is eligible for ICR Sponsorship. Support will be provided for costs associated with Visa application and health surcharge
Duration of Contract: Fixed Term until 31 July 2025
Hours per week: 35 hours per week (Full Time)
Closing Date: 24th August 2022. Interviews to be held during wc 12th September 2022
Job Details
Research Lead: Professor Andrew Tutt
Summary of Role
A Post Doctoral Training Fellow position is available to start immediately to drive forward high-level research on DNA damage repair biology and cancer target validation. You will be responsible for the design and implementation of a project aimed at establishing new therapeutic approaches to breast cancer, based on DNA damage response and target validation studies. This project will build on previous findings of the group in characterising and targeting HORMAD1 expression in breast cancer (Watkins et al. 2015, Tarantino et al. 2022 and unpublished data). This may involve studying the role of HORMAD1 in replication stress, cell division and other processes dysregulated in breast cancer.
General information on The ICR Post Doc’s can be found here.
Key Requirements
The successful candidate must have a PhD in biology, genetics or other associated subjects and have a strong track record in biomedical research as demonstrated by high-impact, first author publications.
The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years
Department/Directorate Information:
Professor Tutt is the Head of the Breast Cancer Research Division at the ICR and has interests in therapy development for BRCA1/2 associated and “triple negative” (TN) forms of breast cancer. His laboratories at ICR and King’s College London (KCL) have contributed highly to the field (For example, Tutt et al. Nature Medicine 2018; Watkins et al. Cancer Discovery 2015). Working in close partnership with Professor Chris Lord a major focus of the lab is using information from patients being treated in the clinic to identify determinants of PARPi resistance and sensitivity. The majority of the projects focus on developing novel therapeutic approaches to cancer and identifying biomarkers and relevant targets in breast cancer underlying the biology of the disease.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Stephen Pettitt via email [email protected]
About The Institute of Cancer Research
Why work for us?
As a member of staff, you’ll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.